http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 01 Aug 2025 16:30:48 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Sirona+Biochem+faces+financial+challenges%2C+closes+French+subsidiary/25137183.html <p>Sirona Biochem Corp. (TSX-V: SBM) reported that its convertible debenture financing announced in April failed to attract sufficient investor participation. The Vancouver-based company stated that management has operated without salary for two years and personally contributed funds to maintain operations.</p><p>The company entered an investment agreement with Promura GmbH in April, but the committed funds were never received despite multiple assurances and delays. Sirona concluded the investment will not materialize.</p><p>Due to limited financing options, Sirona decided to allow the orderly liquidation of its wholly owned subsidiary TFChem in accordance with French bankruptcy regulations. All laboratory operations have ceased and the facility http://www.streetinsider.com/Corporate+News/Sirona+Biochem+faces+financial+challenges%2C+closes+French+subsidiary/25137183.html Fri, 01 Aug 2025 16:30:48 -0400 SBM SRBCF ZSB http://www.streetinsider.com/Corporate+News/Sirona+Biochem+faces+financial+challenges%2C+closes+French+subsidiary/25137183.html <p>Sirona Biochem Corp. (TSX-V: SBM) reported that its convertible debenture financing announced in April failed to attract sufficient investor participation. The Vancouver-based company stated that management has operated without salary for two years and personally contributed funds to maintain operations.</p><p>The company entered an investment agreement with Promura GmbH in April, but the committed funds were never received despite multiple assurances and delays. Sirona concluded the investment will not materialize.</p><p>Due to limited financing options, Sirona decided to allow the orderly liquidation of its wholly owned subsidiary TFChem in accordance with French bankruptcy regulations. All laboratory operations have ceased and the facility http://www.streetinsider.com/Corporate+News/Sirona+Biochem+faces+financial+challenges%2C+closes+French+subsidiary/25137183.html Fri, 01 Aug 2025 16:30:48 -0400 SBM SRBCF ZSB http://www.streetinsider.com/Corporate+News/Sirona+Biochem+faces+financial+challenges%2C+closes+French+subsidiary/25137183.html <p>Sirona Biochem Corp. (TSX-V: SBM) reported that its convertible debenture financing announced in April failed to attract sufficient investor participation. The Vancouver-based company stated that management has operated without salary for two years and personally contributed funds to maintain operations.</p><p>The company entered an investment agreement with Promura GmbH in April, but the committed funds were never received despite multiple assurances and delays. Sirona concluded the investment will not materialize.</p><p>Due to limited financing options, Sirona decided to allow the orderly liquidation of its wholly owned subsidiary TFChem in accordance with French bankruptcy regulations. All laboratory operations have ceased and the facility http://www.streetinsider.com/Corporate+News/Sirona+Biochem+faces+financial+challenges%2C+closes+French+subsidiary/25137183.html Fri, 01 Aug 2025 16:30:48 -0400 SBM SRBCF ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html <p align="left">VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- <em>Sirona Biochem Corp.</em> (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.</p> <p>The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.</p> <p>After an http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Update+to+Shareholders+on+Financial+Status+and+Operations/25137156.html Fri, 01 Aug 2025 16:30:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Press+Releases/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Announces+Debenture+Financing/24668421.html <p align="justify">VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JqKp_x6ZjzhhMvpGiec6N5EHD8MC_RjRL9_DP9o6F-BhciGIR0dLYr1JwA29G5emNDFyYbRTPpzMOdZRwkYZfF9Idot4DB9gwPg2m9PI-Hw=" rel="nofollow" target="_blank">Sirona Biochem Corp</a>. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“<strong>Sirona</strong>” or the “<strong>Company</strong>”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “<strong>Convertible Debentures</strong>”). The Convertible Debentures will be offered in units (the “<strong>Debenture Units</strong>”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “<strong>Offering</strong>”). The Company plans to use the proceeds of the Offering for general corporate purposes.</p> <p align="justify">Each Debenture Unit will have a face value of (the http://www.streetinsider.com/Globe+Newswire/Sirona+Biochem+Announces+Debenture+Financing/24668421.html Tue, 22 Apr 2025 14:55:00 -0400 A.50208731 O.02555813 O.05079501 SBM SRBCF ZSB ZSB